Literature DB >> 26653188

Treatment of Tuberculosis. A Historical Perspective.

John F Murray1, Dean E Schraufnagel2, Philip C Hopewell1.   

Abstract

Of all achievements in medicine, the successful treatment of tuberculosis has had one of the greatest impacts on society. Tuberculosis was a leading cause of disease and a mortal enemy of humanity for millennia. The first step in finding a cure was the discovery of the cause of tuberculosis by Robert Koch in 1882. The sanatorium movement that began shortly afterward in Europe, and soon spread to the United States, brought attention to the plight of afflicted persons, and catalyzed public health action. The antituberculosis benefit of streptomycin was announced in 1945, although application was limited by the rapid development of resistance. para-Aminosalicylic acid, also discovered in 1945, when combined with streptomycin was found to greatly reduce the occurrence of drug resistance. In 1952, isoniazid opened the modern era of treatment; it was inexpensive, well tolerated, and safe. In the early 1960s, ethambutol was shown to be effective and better tolerated than para-aminosalicylic acid, which it replaced. In the 1970s, rifampin found its place as a keystone in the therapy of tuberculosis. The use of rifampin enabled the course of treatment to be reduced to nine months. Incorporation of pyrazinamide into the first-line regimen led to a further reduction of treatment duration to six months. Treatment of multiple drug-resistant tuberculosis remains a difficult problem requiring lengthy treatment with toxic drugs. However, shortened regimens show promise, and two new drugs, bedaquiline and delamanid, have demonstrated effectiveness in preliminary studies and are being used for extensively drug-resistant tuberculosis.

Entities:  

Keywords:  chemotherapy; drug development; history

Mesh:

Substances:

Year:  2015        PMID: 26653188     DOI: 10.1513/AnnalsATS.201509-632PS

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  30 in total

Review 1.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

2.  Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.

Authors:  Alice L den Hertog; Sandra Menting; Richard Pfeltz; Matthew Warns; Salman H Siddiqi; Richard M Anthony
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 3.  Recent trends on hydrogel based drug delivery systems for infectious diseases.

Authors:  Arti Vashist; Ajeet Kaushik; Atul Vashist; Rahul Dev Jayant; Asahi Tomitaka; Sharif Ahmad; Y K Gupta; Madhavan Nair
Journal:  Biomater Sci       Date:  2016-10-18       Impact factor: 6.843

4.  Closing the book on Category II: time for individualized regimens for patients with recurrent tuberculosis.

Authors:  Sara C Auld; Neel R Gandhi; N Sarita Shah
Journal:  Int J Tuberc Lung Dis       Date:  2018-10-01       Impact factor: 2.373

Review 5.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

6.  Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.

Authors:  Nada Lelovic; Katsuhiko Mitachi; Junshu Yang; Maddie R Lemieux; Yinduo Ji; Michio Kurosu
Journal:  J Antibiot (Tokyo)       Date:  2020-05-29       Impact factor: 2.649

7.  Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).

Authors:  Pooja V Hegde; Michael D Howe; Matthew D Zimmerman; Helena I M Boshoff; Sachin Sharma; Brianna Remache; Ziyi Jia; Yan Pan; Anthony D Baughn; Veronique Dartois; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2022-02-19       Impact factor: 6.514

8.  Hear us! Accounts of people treated with injectables for drug-resistant TB.

Authors:  A Almeida; M Adjuntsov; W Bushura; E Delgado; M Drasher; M Fernando-Pancho; M Gasane; M V Ianoşi; E Lessem; A Musah; Ş Răduţ; C H Sánchez Ríos; K S Soe; N Venkatesan; V V Villegas; J Stillo
Journal:  Public Health Action       Date:  2021-09-21

9.  Rifampicin Transport by OATP1B1 Variants.

Authors:  Carlijn H C Litjens; Jeroen J M W van den Heuvel; Frans G M Russel; Rob E Aarnoutse; Lindsey H M Te Brake; Jan B Koenderink
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

10.  Heterogeneous Streptomycin Resistance Level Among Mycobacterium tuberculosis Strains From the Same Transmission Cluster.

Authors:  Deisy M G C Rocha; Carlos Magalhães; Baltazar Cá; Angelica Ramos; Teresa Carvalho; Iñaki Comas; João Tiago Guimarães; Helder Novais Bastos; Margarida Saraiva; Nuno S Osório
Journal:  Front Microbiol       Date:  2021-06-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.